Vaccinex (VCNX -1.5%) announces full enrollment (n=62) in a Phase 1b/2 clinical trial, CLASSICAL-Lung, evaluating lead candidate pepinemab (VX15/2503), combined with Pfizer’s (PFE +0.6%) Bavencio (avelumab), in patients with advanced non-small cell lung cancer (NSCLC).
The primary completion date should be in H2.
Preliminary data presented at ASCO showed a 63% (n=10/16) clinical benefit rate (responders + stable cancer).
The company is collaborating with Pfizer and Merck KGaA (OTCPK:MKGAY+0.8%) on the trial.
Pepinemab is a humanized monoclonal antibody that blocks the signaling of a protein called SEMA4K thereby promoting the infiltration of immune cells into cancer cells.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.